Welcome to InfiCure Bio
InfiCure Bio is a life science company focusing on preclinical development and validation of drugs that target chronic inflammatory and fibrotic conditions.
Based on a panel of in vivo models for these conditions including a proprietary model for chronic inflammation and fibrosis, we offer effect tests of anti-inflammatory and anti-fibrotic drugs.
Founded on extensive experience and expertise in immunology, inflammation and fibrosis research, InfiCure Bio offers a proficient and flexible processing of drug validation projects in this area.
News
NASH summit in Frankfurt
InfiCure Bio is present at the 2nd NASH summit in Europe held in Frankfurt. We are presenting our new models for NASH, the NIF-HFD mouse and the MEL-HFD mouse. InfiCure did also moderate the round [...]
InfiCure Bio is nominated in the category “Spin-off company of the year”
InfiCure Bio is nominated in the category "Spin-off company of the year" at UmeåGalan 2018 and we are very happy and excited about it. UmeåGalan will be held on November 8th and this is an [...]
New publication on the N-IF mouse
We are happy to announce that a new publication on the N-IF mouse is published in Plos One. The publication shows treatment of liver fibrosis in the N-IF mouse and the results verify that the fibrosis, which [...]
Inficure Bio in collaboration with global biotech company CSL
We are proud to announce that InfiCure Bio has signed a collaboration agreement with the global biotech company CSL (https://www.csl.com). The signing of the contract entails collaboration between InfiCure Bio and CSL in testing [...]